Redhill Biopharma Ltd. (NASDAQ:RDHL) Shares Shorted: Short Interest Up 2,710.1% in September

Redhill Biopharma Ltd. (NASDAQ:RDHL) was the recipient of a significant growth in short interest during the month of September. As of September 15th, there was short interest totaling 235,258 shares, a growth of 2,710.1% from the August 31st total of 8,372 shares. Approximately 4.2% of the shares of the stock are sold short. Based on an average trading volume of 748,437 shares, the days-to-cover ratio is currently 0.3 days.

Analyst Upgrades and Downgrades

Separately, Weiss Ratings reiterated a “sell (d-)” rating on shares of Redhill Biopharma in a report on Monday, August 3rd. One investment analyst has rated the stock with a Sell rating, Based on data from MarketBeat, the company currently has a consensus rating of “Sell”.

Institutional Trading of Redhill Biopharma

An institutional investor recently bought a new stake in Redhill Biopharma stock. Yorkville Advisors Global LP purchased a new stake in shares of Redhill Biopharma Ltd. (NASDAQ:RDHL) during the 4th quarter, according to the company in its most recent disclosure with the SEC. The fund purchased 386,593 shares of the biotechnology company’s stock, valued at approximately $398,000. Redhill Biopharma accounts for approximately 0.3% of Yorkville Advisors Global LP’s holdings, making the stock its 19th biggest holding. Yorkville Advisors Global LP owned about 7.57% of Redhill Biopharma at the end of the most recent reporting period. 7.20% of the stock is currently owned by institutional investors and hedge funds.

Redhill Biopharma Stock Performance

Shares of RDHL stock traded down $0.01 on Friday, hitting $0.51. 18,855 shares of the stock traded hands, compared to its average volume of 851,314. Redhill Biopharma has a twelve month low of $0.51 and a twelve month high of $2.79. The stock has a market capitalization of $3.13 million, a PE ratio of 0.00 and a beta of 4.96. The firm’s 50-day moving average price is $0.64 and its two-hundred day moving average price is $0.80.

Redhill Biopharma Company Profile

RedHill Biopharma Ltd. was a specialty biopharmaceutical company focused on developing and commercializing therapies for gastrointestinal diseases and certain infectious diseases. The company was founded in Israel and conducted operations primarily in the United States, where it pursued regulatory approval, commercialization and clinical development activities.

RedHill’s principal commercial product was Talicia, an oral combination of rifabutin, amoxicillin and omeprazole approved by the U.S.